National Bank Financial Raises DRI Healthcare Trust (TSE:DHT.UN) Price Target to C$25.50

DRI Healthcare Trust (TSE:DHT.UN) had its price target increased by analysts at National Bank Financial from C$23.50 to C$25.50 in a research note issued on Tuesday, BayStreet reports. The brokerage currently has an “outperform” rating on the stock. National Bank Financial’s price target suggests a potential upside of 38.21% from the stock’s current price.

Other analysts have also recently issued reports about the company. Raymond James Financial boosted their price target on DRI Healthcare Trust from C$22.50 to C$23.50 and gave the stock a “strong-buy” rating in a research report on Monday, June 29th. Stifel Nicolaus lifted their target price on shares of DRI Healthcare Trust from C$25.00 to C$26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Canaccord Genuity Group upped their target price on shares of DRI Healthcare Trust from C$22.25 to C$23.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. Based on data from MarketBeat.com, DRI Healthcare Trust currently has an average rating of “Buy” and a consensus target price of C$25.60.

DRI Healthcare Trust Price Performance

DHT.UN stock traded up C$0.73 during trading on Tuesday, hitting C$18.45. The stock had a trading volume of 77,329 shares, compared to its average volume of 56,188. DRI Healthcare Trust has a twelve month low of C$14.10 and a twelve month high of C$19.75. The company’s 50-day moving average price is C$17.61 and its two-hundred day moving average price is C$17.35. The stock has a market capitalization of C$1.02 billion, a P/E ratio of -23.06 and a beta of 0.37.

DRI Healthcare Trust Company Profile

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare’s units are listed and trade on the TSX in Canadian dollars under the symbol ‘DHT.UN’ and in U.S. dollars under the symbol ‘DHT.U’. To learn more, visit drihealthcare.com or follow us on LinkedIn.